Autonomic Nervous System and Meridian Energy in Patients With Schizophrenia
Trial Parameters
Brief Summary
This study aims to explore the differences in autonomic nervous function and meridian energy between schizophrenia patients and healthy individuals. By understanding the meridian and organ conditions of individuals, the study aims to align with the traditional Chinese medicine (TCM) concept of "treating disease before it arises" and provide comprehensive care to patients, thereby improving the quality of care.
Eligibility Criteria
Inclusion Criteria: 1. Disease group： * Diagnosed with schizophrenia by a physician (ICD-10 code F20, such as F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, or F20.9), with stable condition, and has not had any changes in medication dosage or admission to a psychiatric acute care unit in the past 3 months. * Aged between 18 and 65 years. * Able to understand, speak, read, and write Mandarin or Taiwanese. 2. Control group： * No history of chronic illness and no acute symptoms within the past month. * Aged between 18 and 65 years. * Able to understand, speak, read, and write Mandarin or Taiwanese. Exclusion Criteria: 1. Disease group： * Individuals with cardiovascular conditions, severe neurological disorders (e.g., organic brain disorders, early-stage dementia or diagnosed dementia), or substance abuse issues. * Individuals who have used medications affecting the autonomic nervous system within the past month, such as mood stabilizers, antidepressants, angiotensin-converting enzyme inhibito